Avalon Globocare Corp   (ALBT)
Other Ticker:  
Price: $0.3610 $-0.03 -7.767%
Day's High: $0.415 Week Perf: -7.44 %
Day's Low: $ 0.36 30 Day Perf: -9.07 %
Volume (M): 2,526 52 Wk High: $ 3.87
Volume (M$): $ 912 52 Wk Avg: $1.19
Open: $0.38 52 Wk Low: $0.36

 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Avalon Globocare Corp
Avalon Globocare Corp is a biotechnology company that primarily focuses on developing and commercializing innovative cell-based technologies and therapeutics. The company operates in the United States and China and has a wide range of healthcare and wellness products in its portfolio. Avalon Globocare Corp aims to transform the field of healthcare by using cutting-edge technologies such as gene therapy, cellular immunotherapy, and regenerative medicine. Their goal is to provide advanced and personalized treatment options to patients, ultimately improving their quality of life.

   Company Address: 4400 Route 9 South Freehold 7728 NJ
   Company Phone Number: 780-4400   Stock Exchange / Ticker: NASDAQ ALBT
   ALBT is expected to report next financial results on March 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


Avalon GloboCare Collaborates with ChtrBx to Introduce KetoAir in Multiple Global Markets

Published Mon, Dec 18 2023 2:00 PM UTC

Avalon GloboCare Corp. (NASDAQ: ALBT), a prominent developer of innovative precision diagnostics and provider of clinical laboratory services, has recently enlisted the expertise of ChtrBx, a renowned marketing and branding company. This strategic partnership aims to create an extensive marketing launch plan for KetoAir, Avalon GloboCare's groundbreaking product. W...

Avalon Globocare Corp

Avalon Globocare Corp Defies Market Conditions with Surging Revenue Growth

Avalon Globocare Corp, a company in the Biotechnology & Pharmaceuticals industry, has recently reported its financial performance for the most recent fiscal period. Despite the challenging market conditions, the company has managed to buck the trend and achieve a top-line surge.
In the latest reporting season, Avalon Globocare Corp recorded a net deficit per share of $-0.14, a slight decrease compared to the previous year's figure of $-0.06. However, the company experienced a significant increase in revenue, which advanced by 4.379% to $0.33 million from the same reporting season a year before. This growth in revenue is in stark contrast to many of its peers in the Biotechnology & Pharmaceuticals industry, who saw a contraction in revenue during the same period.

Avalon Globocare Corp

Avalon Globocare Corp Faces Financial Challenges with Increasing Losses Despite Revenue Growth in 2023

Avalon Globocare Corp, a leading biotechnology company, recently released its financial results for the interval closing June 30, 2023. The report showcased a mixed bag of results, with losses per share increasing compared to the previous year, while earnings per share saw an improvement.
During this period, Avalon Globocare Corp suffered losses of $0.25 per share, a significant jump from the $0.02 loss per share incurred a year before. However, there was a positive development in terms of earnings per share, which increased from the $0.28 loss per share reported in the preceding financial reporting period.

Avalon Globocare Corp

Avalon Globocare Corp Reports Expanded Financial Losses and Diminishing Returns amid Revenue Depletion for Fiscal Period Ending March 31, 2023

The stock market is a constantly evolving arena, where market movements and financial reporting can greatly affect investors and businesses alike. However, despite the recent depleting orders and losses in the financial time-frame closing March 31, 2023, there are still reasons to look to the future with optimism.
Despite revenue falling by -0.493% to $0.30 million and a loss per share at $-0.28, it?s important to note that the previous financial reporting period showed a loss of $-0.03 per share. Furthermore, it?s important to remember that in any market there will always be ups and downs, and that it?s the long-term prospects that matter most when making investment decisions.


Avalon Globocare's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com